|
Gestonorone caproate
|
DB14677 |
|
|
Fagrocorat
|
DB14676 |
|
|
Alpelisib
|
DB12015 |
[Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation.[A179209]
There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL).[A179209] Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer [A179200] and colorectal cancer [A179203], are under ongoing investigations.
Alpelisib was granted FDA approval on 24 May 2019.[L6652]] |
|
Bufexamac
|
DB13346 |
[Bufexamac is a non-steroidal anti-inflammatory drug (NSAID) under the market name Droxaryl, Malipuran, Paraderm and Parfenac. It is typically administered topically for the treatment of subacute and chronic eczema of the skin, including atopic eczema and other inflammatory dermatoses, as well as sunburn and other minor burns, and itching. It has also been used in suppositories in combination with local anaesthetics indicated for haemorrhoids. The use of bufexamac has been discontinued in Canada and the United States, which may be due to undetermined clinical efficacy and a high prevalence of contact sensitization [A32822]. Bufexamac was also withdrawn by the EMA in April 2010.] |
|
Quingestanol acetate
|
DB14679 |
|
|
Ponesimod
|
DB12016 |
[Ponesimod has been used in trials studying the treatment of Psoriasis, Chronic GVHD, Pharmacokinetics, Plaque Psoriasis, and Multiple sclerosis, among others.] |
|
Diphenadione
|
DB13347 |
|
|
Tiadenol
|
DB13348 |
|
|
Ozagrel
|
DB12017 |
[Ozagrel has been used in trials studying the treatment of Dry Eye Syndromes.] |
|
Norethindrone enanthate
|
DB14678 |
|
|
Fenozolone
|
DB13341 |
|
|
Fostamatinib
|
DB12010 |
[Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018 under the trade name Tavalisse for use in ITP [L2644,FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA [L2644].] |
|
Flurandrenolide acetate
|
DB14673 |
|
|
Oxazepam acetate
|
DB14672 |
|
|
Cinepazet
|
DB13342 |
|
|
Fevipiprant
|
DB12011 |
[Fevipiprant has been used in trials studying the treatment of Asthma, Atopic Dermatitis, and Allergic Rhinitis.] |
|
Temsavir
|
DB14675 |
|
|
PF-04457845
|
DB12012 |
[PF-04457845 is under investigation in Fear Conditioning. PF-04457845 has been investigated for the treatment of Tourette Syndrome and Cannabis Dependence.] |
|
Tioxolone
|
DB13343 |
|
|
Axelopran
|
DB12013 |
[Axelopran has been used in trials studying the treatment of OIC and Opioid-induced Constipation.] |
